Analysis of the negative reimbursement of Orphan Drugs in the Spanish National Health System (2019-2022)

//Analysis of the negative reimbursement of Orphan Drugs in the Spanish National Health System (2019-2022)

Analysis of the negative reimbursement of Orphan Drugs in the Spanish National Health System (2019-2022)

Omakase presented a POSTER “Analysis of the negative reimbursement of Orphan Drugs in the Spanish National Health System (2019-2022)” and isour recent analysis conducted on Orphan Drugs which received a negative Pricing & Reimbursement (P&R) decision in Spain and the reasons behind them at World Orphan Drugs 2022.

The findings show that more than half of ODs approved by the EMA do not get a positive P&R decision in their first resolution, mainly related to their budgetary impact and the uncertainty of their clinical benefit. This reduces the likelihood of access for patients, as only one out three of them were finally reimbursed after allegations.

Hope this work contributes to raise awareness on the need to develop a specific process for the evaluation of ODs in Spain, which support their optimal access to patients with rare diseases.

2022-11-24T18:55:21+00:00November 24th, 2022|Abstracts/posters|